We are live on ! Find out more
RG

Redmile Group Portfolio holdings

AUM $1.49B
1-Year Est. Return 208.7%
This Fund
S&P 500
This Quarter Est. Return
-16.16%
1 Year Est. Return
+208.7%
3 Year Est. Return
+777.5%
5 Year Est. Return
+1,114.43%
10 Year Est. Return
+23,630.52%
AUM
$1.06B
AUM Growth
-$377M
Cap. Flow
-$48.8M
Cap. Flow %
-4.62%
Top 10 Hldgs %
61.75%
Holding
64
New
2
Increased
7
Reduced
31
Closed
8
Avg Time Held
14.4 quarters
Top 10 Avg Time Held
6.9 quarters
Top 20 Avg Time Held
7 quarters

Top Buys

Rank Stock Value
1
FOLD icon
Amicus Therapeutics
FOLD
+$22.9M
2
IRTC icon
iRhythm Holdings
IRTC
+$6.02M
3
SLDB icon
Solid Biosciences
SLDB
+$6.01M
4
IMNM icon
Immunome
IMNM
+$5.12M
5
PODD icon
Insulet
PODD
+$4.75M

Top Sells

Rank Stock Value
1
AKRO icon
Akero Therapeutics
AKRO
+$12.5M
2
BSX icon
Boston Scientific
BSX
+$12M
3
SYK icon
Stryker
SYK
+$11M
4
ISRG icon
Intuitive Surgical
ISRG
+$8.84M
5
ARDX icon
Ardelyx
ARDX
+$7.99M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
SRRK icon
1
Scholar Rock
SRRK
$5.01B
$141M 13.37%
4,398,281
-151,600
-3% -$5.83M
2018 Q2
27 quarters
KRYS icon
2
Krystal Biotech
KRYS
$9.58B
$133M 12.57%
737,675
-15,500
-2% -$2.61M
2018 Q4
25 quarters
FOLD icon
3
DELISTED
Amicus Therapeutics
FOLD
$77.8M 7.35%
9,533,669
+2,478,779
+35% +$22.9M
2013 Q2
47 quarters
ZYME icon
4
Zymeworks
ZYME
$1.82B
$57M 5.39%
4,788,945
-51,518
-1% -$703K
2020 Q1
20 quarters
NRIX icon
5
Nurix Therapeutics
NRIX
$2.33B
$48.1M 4.55%
4,051,927
-140,700
-3% -$2.35M
2020 Q3
18 quarters
REPL icon
6
Replimune Group
REPL
$1.17B
$47.8M 4.51%
4,898,527
-7,000
-0.1% -$86.6K
2018 Q3
26 quarters
LIVN icon
7
LivaNova
LIVN
$4.23B
$39.8M 3.77%
1,014,139
-29,400
-3% -$1.32M
2021 Q1
16 quarters
AKRO icon
8
DELISTED
Akero Therapeutics
AKRO
$38M 3.59%
939,277
-295,932
-24% -$12.5M
2019 Q2
23 quarters
IMNM icon
9
Immunome
IMNM
$2.09B
$36.1M 3.41%
5,361,187
+533,161
+11% +$5.12M
2023 Q4
5 quarters
RGNX icon
10
Regenxbio
RGNX
$479M
$34.3M 3.24%
4,794,780
– –
2017 Q1
32 quarters
BEAM icon
11
Beam Therapeutics
BEAM
$2.54B
$31.4M 2.97%
1,610,329
+81,762
+5% +$2.14M
2020 Q1
20 quarters
STOK icon
12
Stoke Therapeutics
STOK
$1.48B
$29.8M 2.82%
4,485,981
-107,648
-2% -$1M
2019 Q2
23 quarters
KYMR icon
13
Kymera Therapeutics
KYMR
$9.15B
$26.9M 2.54%
983,413
-117,019
-11% -$4.27M
2020 Q3
18 quarters
ADCT icon
14
ADC Therapeutics
ADCT
$216M
$22.1M 2.09%
15,666,731
– –
2020 Q2
19 quarters
BHVN icon
15
Biohaven
BHVN
$1.73B
$20.9M 1.97%
867,454
-37,042
-4% -$1.31M
2023 Q3
6 quarters
ABSI icon
16
Absci
ABSI
$1.61B
$20.7M 1.96%
8,253,316
– –
2021 Q3
14 quarters
BSX icon
17
Boston Scientific
BSX
$62.4B
$19.5M 1.84%
193,283
-119,400
-38% -$12M
2023 Q1
8 quarters
COGT icon
18
Cogent Biosciences
COGT
$4.98B
$19.3M 1.82%
3,216,026
-338,810
-10% -$2.66M
2023 Q2
7 quarters
NGNE icon
19
Neurogene
NGNE
$466M
$15.3M 1.45%
1,308,063
-11,700
-0.9% -$203K
2019 Q4
21 quarters
ETNB icon
20
DELISTED
89bio
ETNB
$13.7M 1.3%
1,886,444
-280,732
-13% -$2.45M
2023 Q1
8 quarters
ESTA icon
21
Establishment Labs
ESTA
$1.79B
$13.7M 1.29%
335,366
+15,217
+5% +$567K
2024 Q1
4 quarters
ANNX icon
22
Annexon
ANNX
$726M
$12.2M 1.15%
6,300,644
– –
2020 Q3
18 quarters
CLDX icon
23
Celldex Therapeutics
CLDX
$2.24B
$10.7M 1.01%
590,175
-25,600
-4% -$572K
2020 Q2
19 quarters
FATE icon
24
Fate Therapeutics
FATE
$247M
$10.2M 0.96%
12,872,946
– –
2015 Q2
39 quarters
IDYA icon
25
IDEAYA Biosciences
IDYA
$3.38B
$8.76M 0.83%
534,600
-84,700
-14% -$1.8M
2023 Q4
5 quarters
1
2 3

Similar funds

FCM
Fairholme Capital Management South Miami, Florida $1.49B AUM 28.35% 1-Year Est. Return
MM
Main Management San Francisco, California $1.49B AUM 22.28% 1-Year Est. Return
WA
WBH Advisory Baltimore, Maryland $1.49B AUM 20.41% 1-Year Est. Return
ACB
Aristotle Capital Boston Boston, Massachusetts $1.49B AUM 32.81% 1-Year Est. Return
LCS
Levin Capital Strategies New York $1.49B AUM 30.44% 1-Year Est. Return
GAM
Gemmer Asset Management Walnut Creek, California $1.49B AUM 42.66% 1-Year Est. Return
MFWP
Mosaic Family Wealth Partners St. Louis, Missouri $1.49B AUM 26.43% 1-Year Est. Return
PMG
ProVise Management Group Clearwater, Florida $1.49B AUM 21.79% 1-Year Est. Return

Redmile Group's Q1 2025 Portfolio in Review

As of Q1 2025, Redmile Group held 64 positions worth $1.06B, down 26% from $1.43B the previous quarter. Its ten largest holdings account for 62% of the portfolio.

Redmile Group withdrew a net $48.8M in Q1 2025, closing 8 positions and reducing 31 holdings. Its most notable exit was Stryker, an estimated $11M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

Against the trend, Redmile Group opened a new position in iRhythm Holdings worth $5.95M.

  • Redmile Group's largest Q1 2025 buy was iRhythm Holdings: 56,844 shares worth $5.95M.
  • Redmile Group added most to Amicus Therapeutics in Q1 2025, an estimated $22.9M increase.
  • Redmile Group's biggest Q1 2025 reduction was Akero Therapeutics, cutting an estimated $12.5M.
  • Redmile Group fully exited Stryker in Q1 2025, selling an estimated $11M.
  • Redmile Group's ten largest holdings make up 62% of its $1.06B portfolio in Q1 2025.
  • Redmile Group opened 2 new positions and closed 8 in Q1 2025.
  • Redmile Group's portfolio value fell 26% quarter-over-quarter to $1.06B.

Based on Redmile Group's 13F filing for Q1 2025, filed 15 May 2025.